Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
it is selectively and irreversibly converted to its active phosphoramidate-based
compound 15b
) lower MAP over 24 hours in normotensive wild-type mice but not in KCa3
LY3372689 can be used for tauopathies research
Dynorphin A also serve as an agonist for other opioid receptors
(-)-Cevimeline hydrochloride hemihydrate Catalog No.:M34745-C it is selectively and irreversibly( ) Cevimeline hydrochloride hemihydrate (( ) SNI 2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI 2011 was also evaluated with rat and dog liver
US$ 130.00
US$ 40.00
US$ 1475.00
US$ 335.00
US$ 1050.00
US$ 160.00
US$ 109.00
US$ 395.00
US$ 187.50